Response Genetics Expands Distribution of ResponseDX(R) Product Portfolio Into International Markets

Response Genetics Expands Distribution of ResponseDX(R) Product Portfolio Into
International Markets

Announces Commercial Agreement to Distribute ResponseDX Testing Into Mexico

LOS ANGELES, May 14, 2014 (GLOBE NEWSWIRE) -- Response Genetics, Inc.
(Nasdaq:RGDX), a company focused on the development and sale of molecular
diagnostic tests that help guide cancer therapy selection, today announced
execution of a commercial agreement with DxM Diagnostico Molecular ("DIFRA"),
a leading distributor for cancer testing in Mexico, to offer the ResponseDX
testing services to patients throughout Mexico.

The agreement covers the ResponseDX: Tissue of Origin™ test as well as the
other targeted molecular tests in the Response Genetics portfolio. The
ResponseDX: Tissue of Origin™ test is an FDA-cleared test that uses gene
expression analysis to provide a definitive diagnosis for
poorly-differentiated or metastatic cancers without a clear primary origin.
The test was acquired by Response Genetics in August 2013 and re-introduced to
the market in February 2014.

Cancer is currently the second leading cause of death in Mexico, with
approximately 125,000 new cases each year and projections for doubling to
250,000 new cases per year by 2030.^1 DIFRA will market the ResponseDX
portfolio through presentations to hospitals and physician practices including
presenting the ResponseDX: Tissue of Origin™ test to oncologists, physicians
and key opinion leaders at the June 2014 Best of ASCO meeting in Mexico City.

"We believe the ResponseDX^® offerings, including our new and recently
introduced proprietary Tissue of Origin test provides differentiated content
to effectively pursue international market opportunities" said Thomas Bologna,
Chairman and Chief Executive Officer of Response Genetics. "One of our
initiatives is to increase access to our testing services both domestically
and internationally. DIFRA will facilitate access to the full complement of
our portfolio to Mexican oncologists and pathologists. We believe our
extensive molecularly-focused solid tumor menu coupled with high service
levels and market-leading innovation will provide Mexico's cancer community
with optimal options for the therapy-selection decision-making tools they

The new agreement is the first in Central America for Response Genetics, as
the company continues to expand its testing services including profiles for
lung, colon, gastric, breast, and thyroid cancers and melanoma into
international markets. The company is pursuing distribution agreements in
Asia, Europe and the Middle East.

About Response Genetics, Inc.

Response Genetics, Inc. (the "Company") is a CLIA-certified clinical
laboratory focused on the development and sale of molecular diagnostic testing
services for cancer. The Company's technologies enable extraction and analysis
of genetic information derived from tumor cells stored as formalin-fixed and
paraffin-embedded specimens. The Company's principal customers include
oncologists and pathologists. In addition to diagnostic testing services, the
Company generates revenue from the sale of its proprietary analytical
pharmacogenomic testing services of clinical trial specimens to the
pharmaceutical industry. The Company's headquarters is located in Los Angeles,
California. For more information, please visit


Forward-Looking Statement Notice

Except for the historical information contained herein, this press release and
the statements of representatives of the Company related thereto contain or
may contain, among other things, certain forward-looking statements, within
the meaning of the Private Securities Litigation Reform Act of 1995.

Such forward-looking statements involve significant risks and uncertainties.
Such statements may include, without limitation, statements with respect to
the Company's plans, objectives, projections, expectations and intentions,
such as the ability of the Company, to provide clinical testing services to
the medical community, to continue to strengthen and expand its sales force,
to continue to build its digital pathology initiative, to attract and retain
qualified management, to continue to strengthen marketing capabilities, to
expand the suite of ResponseDX^® products, to continue to provide the
ResponseDX: Tissue of Origin™ test, to continue to provide clinical trial
support to pharmaceutical clients, to enter into new collaborations with
pharmaceutical clients, to enter into areas of companion diagnostics, to
continue to execute on its business strategy and operations, to continue to
analyze cancer samples and the potential for using the results of this
research to develop diagnostic tests for cancer, the usefulness of genetic
information to tailor treatment to patients, and other statements identified
by words such as "project," "may," "could," "would," "should," "believe,"
"expect," "anticipate," "estimate," "intend," "plan" or similar expressions.

These statements are based upon the current beliefs and expectations of the
Company's management and are subject to significant risks and uncertainties,
including those detailed in the Company's filings with the Securities and
Exchange Commission. Actual results, including, without limitation, actual
sales results, if any, or the application of funds, may differ from those set
forth in the forward-looking statements. These forward-looking statements
involve certain risks and uncertainties that are subject to change based on
various factors (many of which are beyond the Company's control). The Company
undertakes no obligation to publicly update forward-looking statements,
whether because of new information, future events or otherwise, except as
required by law.

CONTACT: Investor Relations Contact:
         Peter Rahmer
         Trout Group
         Company Contact:
         Thomas A. Bologna
         Chairman & Chief Executive Officer

Response Genetics Logo
Press spacebar to pause and continue. Press esc to stop.